L1CAM expression could serve as a biomarker for predicting clinical outcome and response to therapy in patients with endometrioid ovarian carcinoma, but not in clear cell carcinomas. L1CAM positivity also predicts poor outcome in patients with concurrent endometrioid ovarian and endometrial carcinomas.

No abstract

Disease stage and grade are independent clinical prognostic factors in endometrioid ovarian carcinoma.• 3-tier grading system is supported by distinct survival and gradual change of markers between grades.• Markers of favorable outcome were PR, ER, nuclear β-catenin and vimentin positivity.• Abnormal expression of p53, overexpression of p16 and L1CAM positivity were associated with aggressive disease.